VCYT Q4 2021 Earnings — Veracyte, Inc. Revenue & Financial Results | Market Cap Arena

VCYTVeracyte, Inc.

$3B

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$67M+95.0% YoY

Gross Profit

$44M66.0% margin

Operating Income

-$12M-18.3% margin

Net Income

-$11M-15.6% margin

EPS (Diluted)

$-0.15

QoQ Revenue Growth

+11.5%

Cash Flow

Operating Cash Flow

$8M

Free Cash Flow

$8M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$1.2B

Total Liabilities

$91M

Stockholders' Equity

$1.1B

Cash & Equivalents

$173M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$67M	$35M	+95.0%
Gross Profit	$44M	$23M	+90.4%
Operating Income	-$12M	-$8M	-52.8%
Net Income	-$11M	-$8M	-30.9%

Revenue Segments

Testing

$16M59%

Biopharmaceutical And Other

$11M41%